Santen Pharmaceutical Co., Ltd. (SNPHF)
| Market Cap | 3.54B +8.8% |
| Revenue (ttm) | 1.80B -0.7% |
| Net Income | 237.94M +22.8% |
| EPS | 0.73 +30.6% |
| Shares Out | n/a |
| PE Ratio | 14.86 |
| Forward PE | n/a |
| Dividend | 0.25 (1.93%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 2,000 |
| Open | 13.05 |
| Previous Close | 13.05 |
| Day's Range | 10.99 - 13.05 |
| 52-Week Range | 8.88 - 13.06 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that ... [Read more]
Financial Performance
In fiscal year 2026, Santen Pharmaceutical's revenue was 291.62 billion, a decrease of -2.79% compared to the previous year's 300.00 billion. Earnings were 37.36 billion, an increase of 3.07%.
Financial numbers in JPY Financial StatementsNews
Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
(RTTNews) - Ligand Pharmaceuticals Inc. (LGND), announced on Tuesday that it has acquired royalty and milestone payment rights tied to Santen Pharmaceutical Co. Ltd's Ryjunea, the first approved pharm...
Santen Pharmaceutical Slides: FY 2026
Santen Pharmaceutical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 19, 2026.
Clearside Biomedical’s partner signed new collaboration agreement with Santen
Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, ...
Ocular Therapeutix appoints Graves to board of directors
Ocular Therapeutix (OCUL) announced the appointment of Adrienne Graves, Ph.D., to its Board of Directors. As the former CEO of Santen (SNPHY), the US subsidiary of a 130-year-old Japanese pharmaceutic...
Santen Pharmaceutical upgraded to Buy from Neutral at Citi
Citi analyst Hidemaru Yamaguchi upgraded Santen Pharmaceutical to Buy from Neutral with a price target of 1,400 yen, up from 1,100 yen. The analyst says the company’s restructuring-led profit recovery...